<DOC>
	<DOC>NCT01542866</DOC>
	<brief_summary>This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status.</brief_summary>
	<brief_title>A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients with CNV secondary to AMD and not other causes in at least one eye identified by the investigator to be eligible for ranibizumab treatment Patients with a BCVA letter score in the study eye is 24 or better using an ETDRS chart measured at 4 meters distance Patients with any concurrent ocular condition that may result in visual loss during the study Patients with past (within the prior 6 months) or current use of, or likely need for, systemic medications that are known to be toxic to the lens, retina, or optic nerve Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>Age related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Health Management Tool</keyword>
	<keyword>HMT</keyword>
	<keyword>Best Corrected Visual Acuity</keyword>
	<keyword>Investigator's Clinical Judgement of Change</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Central Retinal Subfield Thickness</keyword>
	<keyword>visual function self test</keyword>
</DOC>